ATE490778T1 - Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion - Google Patents

Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion

Info

Publication number: ATE490778T1
Authority: AT; Austria
Prior art keywords: treatment; infection; äetvalü4; mealaü3; ciclosporin
Prior art date: 2004-10-01

Application number

AT05791430T

Other languages

English (en)

Inventor

Pietro Scalfaro

Jean-Maurice Dumont

Gregoire Vuagniaux

Rolland-Yves Mauvernay

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-01

Filing date

2005-10-03

Publication date

2010-12-15

2005-10-03 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE490778T1 publication Critical patent/ATE490778T1/de

Links

229960001265 ciclosporin Drugs 0.000 title abstract 2
208000005176 Hepatitis C Diseases 0.000 title 1
208000010710 hepatitis C virus infection Diseases 0.000 title 1
239000013543 active substance Substances 0.000 abstract 2
102000001493 Cyclophilins Human genes 0.000 abstract 1
108010068682 Cyclophilins Proteins 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
230000027455 binding Effects 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Virology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT05791430T 2004-10-01 2005-10-03 Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion ATE490778T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2004003205		2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en)	2004-10-01	2005-10-03	Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number	Publication Date
ATE490778T1 true ATE490778T1 (de)	2010-12-15

Family

ID=34959441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05791430T ATE490778T1 (de)	2004-10-01	2005-10-03	Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion

Country Status (29)

Country	Link
US (3)	US7439227B2 (de)
EP (1)	EP1793844B1 (de)
JP (1)	JP4892486B2 (de)
KR (1)	KR101191833B1 (de)
CN (1)	CN101056648B (de)
AT (1)	ATE490778T1 (de)
AU (1)	AU2005290984B2 (de)
BR (1)	BRPI0515494A (de)
CA (1)	CA2580448C (de)
CY (1)	CY1114594T1 (de)
DE (1)	DE602005025232D1 (de)
DK (1)	DK1793844T3 (de)
EA (1)	EA012650B1 (de)
ES (1)	ES2357587T3 (de)
GE (1)	GEP20104960B (de)
HR (1)	HRP20110169T1 (de)
IL (1)	IL182362A0 (de)
MA (1)	MA28950B1 (de)
MX (1)	MX2007003387A (de)
NZ (1)	NZ554412A (de)
PL (1)	PL1793844T3 (de)
PT (1)	PT1793844E (de)
RS (1)	RS51614B (de)
SG (1)	SG139750A1 (de)
SI (1)	SI1793844T1 (de)
TN (1)	TNSN07084A1 (de)
UA (1)	UA88484C2 (de)
WO (1)	WO2006038088A1 (de)
ZA (1)	ZA200702610B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
BRPI0513370A (pt)	2004-07-14	2008-05-06	Novartis Ag	uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
US7196161B2 (en)	2004-10-01	2007-03-27	Scynexis Inc.	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ES2314731T3 (es)	2004-11-22	2009-03-16	Astellas Pharma Inc.	Analogo de ciclosporina.
NZ555142A (en) *	2004-12-23	2010-03-26	Novartis Ag	Compounds for flaviviridae treatment
WO2006071619A1 (en)	2004-12-23	2006-07-06	Novartis Ag	Compositions for hcv treatment
RU2427372C2 (ru) *	2005-06-17	2011-08-27	Новартис Аг	Применение санглиферина для лечения вируса гепатита с
WO2007041631A1 (en)	2005-09-30	2007-04-12	Scynexis, Inc.	ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
WO2007041632A2 (en)	2005-09-30	2007-04-12	Scynexis, Inc.	Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
KR101273681B1 (ko)	2005-10-26	2013-06-25	아스텔라스세이야쿠 가부시키가이샤	신규 시클릭 펩티드 화합물
EP2518079A3 (de)	2006-04-11	2012-12-12	Novartis AG	HCV/HIV-Hemmer und Benutzung davon
CA2652662C (en)	2006-05-19	2015-11-03	Scynexis, Inc.	Methods for the treatment and prevention of ocular disorders
KR20090083902A (ko) *	2006-10-12	2009-08-04	노파르티스 아게	개질된 사이클로스포린의 용도
WO2008069917A2 (en)	2006-11-20	2008-06-12	Scynexis, Inc.	Novel cyclic peptides
EP2150269B1 (de)	2007-05-02	2012-11-21	Astellas Pharma Inc.	Neue zyklische peptidverbindungen
US8394763B2 (en)	2007-09-26	2013-03-12	Oregon Health & Science University	Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) *	2008-02-08	2009-08-13	Debiopharm Sa	Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
JP5820722B2 (ja)	2008-06-06	2015-11-24	スシネキスインク	シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US20090306033A1 (en) *	2008-06-06	2009-12-10	Keqiang Li	Novel cyclic peptides
CN102202679B (zh)	2008-11-06	2014-05-07	帝柏奥研究制药有限公司	环十一缩酚酸肽化合物及其作为药物的用途
US8536114B2 (en)	2008-12-31	2013-09-17	Scynexis, Inc.	Macrocycles
RU2492181C2 (ru)	2009-01-30	2013-09-10	Энанта Фармасьютикалс, Инк.	Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
WO2011063076A1 (en)	2009-11-19	2011-05-26	Itherx Pharmaceuticals, Inc.	Methods of treating hepatitis c virus with oxoacetamide compounds
CN102869367A (zh)	2009-12-09	2013-01-09	西尼克斯公司	新颖的环肽
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
WO2011141891A1 (en)	2010-05-12	2011-11-17	Debio Recherche Pharmaceutique S.A.	Use of cycloundecadepsipeptide compounds
US9217015B2 (en)	2010-07-16	2015-12-22	S&T Global Inc.	Cyclosporin derivatives for the treatment and prevention of a viral infection
CN103153330B (zh)	2010-08-12	2017-08-18	美国科技环球有限公司	新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
WO2012045704A1 (en) *	2010-10-05	2012-04-12	Novartis Ag	New treatments of hepatitis c virus infection
CN103179966B (zh)	2010-10-08	2017-03-15	诺瓦提斯公司	磺酰胺ns3抑制剂的维生素e制剂
RU2013129824A (ru) *	2010-11-30	2015-01-10	Новартис Аг	Новое лечение инфекции вируса гепатита с
US9890198B2 (en)	2010-12-03	2018-02-13	S&T Global Inc.	Cyclosporin derivatives and uses thereof
JO3337B1 (ar) *	2010-12-13	2019-03-13	Debiopharm Sa	تركيبات صيدلية تشمل أليسبوريفير
KR20140007927A (ko)	2011-03-31	2014-01-20	노파르티스 아게	C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
WO2012131061A1 (en)	2011-04-01	2012-10-04	Novartis Ag	Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
RU2013150344A (ru) *	2011-04-13	2015-05-20	Новартис Аг	Лечение инфекции вируса гепатита алисповиром
US20140228281A1 (en)	2011-09-27	2014-08-14	Novartis Ag	Alisporivr for treatment of hepatitis c virus infection
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
DE112012003510T5 (de)	2011-10-21	2015-03-19	Abbvie Inc.	Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
WO2013169616A1 (en)	2012-05-07	2013-11-14	Novartis Ag	Pharmacokinetic modulation with alisporivir
AR090964A1 (es) *	2012-05-09	2014-12-17	Novartis Ag	Proceso para la elaboracion de undecapeptidos ciclicos
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en)	2012-11-30	2014-07-24	Novartis Ag	Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en)	2013-07-17	2015-01-22	Novartis Ag	Treatment of hepatitis c virus infection with alisporivir and ribavirin
HK1223843A1 (zh)	2013-08-26	2017-08-11	Enanta Pharmaceuticals, Inc.	用於預防或治療丙型肝炎的環孢菌素類似物
WO2015136455A1 (en)	2014-03-13	2015-09-17	Novartis Ag	New treatments of hepatitis c virus infection
US9669095B2 (en)	2014-11-03	2017-06-06	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis C infection
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
TWI780152B (zh)	2017-05-12	2022-10-11	日商中外製藥股份有限公司	環狀有機化合物的製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757522B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) *	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
PT1091975E (pt) *	1998-07-01	2006-05-31	Debiopharm Sa	Nova ciclosporina com um perfil de actividade melhorado
GB0320638D0 (en) *	2003-09-03	2003-10-01	Novartis Ag	Organic compounds

2005
- 2005-10-03 AT AT05791430T patent/ATE490778T1/de active
- 2005-10-03 GE GEAP200510037A patent/GEP20104960B/en unknown
- 2005-10-03 PL PL05791430T patent/PL1793844T3/pl unknown
- 2005-10-03 CN CN2005800332843A patent/CN101056648B/zh not_active Expired - Fee Related
- 2005-10-03 PT PT05791430T patent/PT1793844E/pt unknown
- 2005-10-03 RS RS20110108A patent/RS51614B/sr unknown
- 2005-10-03 CA CA2580448A patent/CA2580448C/en not_active Expired - Fee Related
- 2005-10-03 BR BRPI0515494-4A patent/BRPI0515494A/pt not_active IP Right Cessation
- 2005-10-03 KR KR1020077007285A patent/KR101191833B1/ko not_active Expired - Fee Related
- 2005-10-03 SG SG200800480-6A patent/SG139750A1/en unknown
- 2005-10-03 DK DK05791430.1T patent/DK1793844T3/da active
- 2005-10-03 DE DE602005025232T patent/DE602005025232D1/de not_active Expired - Lifetime
- 2005-10-03 ES ES05791430T patent/ES2357587T3/es not_active Expired - Lifetime
- 2005-10-03 EA EA200700725A patent/EA012650B1/ru not_active IP Right Cessation
- 2005-10-03 HR HR20110169T patent/HRP20110169T1/hr unknown
- 2005-10-03 WO PCT/IB2005/002940 patent/WO2006038088A1/en not_active Ceased
- 2005-10-03 MX MX2007003387A patent/MX2007003387A/es active IP Right Grant
- 2005-10-03 EP EP05791430A patent/EP1793844B1/de not_active Expired - Lifetime
- 2005-10-03 JP JP2007534110A patent/JP4892486B2/ja not_active Expired - Fee Related
- 2005-10-03 SI SI200531225T patent/SI1793844T1/sl unknown
- 2005-10-03 AU AU2005290984A patent/AU2005290984B2/en not_active Ceased
- 2005-10-03 NZ NZ554412A patent/NZ554412A/en not_active IP Right Cessation
- 2005-10-03 UA UAA200704937A patent/UA88484C2/ru unknown
2006
- 2006-04-12 US US11/406,800 patent/US7439227B2/en not_active Ceased
2007
- 2007-03-08 TN TNP2007000084A patent/TNSN07084A1/en unknown
- 2007-03-28 ZA ZA200702610A patent/ZA200702610B/xx unknown
- 2007-04-01 IL IL182362A patent/IL182362A0/en not_active IP Right Cessation
- 2007-04-27 MA MA29858A patent/MA28950B1/fr unknown
2008
- 2008-08-26 US US12/230,198 patent/US7772184B2/en not_active Expired - Fee Related
2010
- 2010-10-29 US US12/915,370 patent/USRE43371E1/en not_active Expired - Fee Related
2011
- 2011-03-08 CY CY20111100263T patent/CY1114594T1/el unknown

Also Published As

Publication number	Publication date
MA28950B1 (fr)	2007-10-01
CN101056648B (zh)	2012-08-15
AU2005290984A1 (en)	2006-04-13
ZA200702610B (en)	2008-08-27
DK1793844T3 (da)	2011-03-21
JP2008514690A (ja)	2008-05-08
IL182362A0 (en)	2007-07-24
EA200700725A1 (ru)	2007-10-26
MX2007003387A (es)	2007-05-23
HK1104236A1 (en)	2008-01-11
DE602005025232D1 (de)	2011-01-20
RS51614B (sr)	2011-08-31
CY1114594T1 (el)	2016-10-05
TNSN07084A1 (en)	2008-06-02
KR20070073761A (ko)	2007-07-10
US7439227B2 (en)	2008-10-21
US20090081164A1 (en)	2009-03-26
US20060252675A1 (en)	2006-11-09
SI1793844T1 (sl)	2011-05-31
SG139750A1 (en)	2008-02-29
CA2580448C (en)	2012-09-18
JP4892486B2 (ja)	2012-03-07
KR101191833B1 (ko)	2012-10-16
AU2005290984B2 (en)	2010-09-09
USRE43371E1 (en)	2012-05-08
NZ554412A (en)	2011-01-28
EP1793844B1 (de)	2010-12-08
UA88484C2 (ru)	2009-10-26
EP1793844A1 (de)	2007-06-13
EA012650B1 (ru)	2009-12-30
BRPI0515494A (pt)	2008-07-29
GEP20104960B (en)	2010-04-26
PT1793844E (pt)	2011-03-10
HRP20110169T1 (hr)	2011-04-30
US7772184B2 (en)	2010-08-10
CN101056648A (zh)	2007-10-17
ES2357587T3 (es)	2011-04-27
CA2580448A1 (en)	2006-04-13
WO2006038088A1 (en)	2006-04-13
PL1793844T3 (pl)	2011-05-31

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1793844

Country of ref document: EP

Publication	Publication Date	Title
DE602005025232D1 (de)	2011-01-20	Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
ATE497775T1 (de)	2011-02-15	Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
WO2006033995A3 (en)	2006-06-01	Thiazolidin-4-ones having anti-hepatitis b activity
DE60119784D1 (de)	2006-06-22	Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
EP1802650A4 (de)	2008-08-20	3-ether- und 3-thioether-substituierte ciclosporinderivate zur behandlung und prävention einer hepatitis-c-infektion
WO2006138418A3 (en)	2007-09-13	Improvement of cognitive performance with sirtuin activators
EA200700243A1 (ru)	2007-08-31	Способы лечения гепатита с
PL384263A1 (pl)	2008-07-21	Wariant oksydazy moczanowej i jego zastosowanie
BR0011838A (pt)	2002-03-05	Elementos misturadores estáticos empilhados
ATE456369T1 (de)	2010-02-15	Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
LT1644009T (lt)	2018-03-12	Kompozicijos telomerazių aktyvumo didinimui ir živ infekcijos gydymui
ITMI20041550A1 (it)	2004-10-29	Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
WO2007092645A3 (en)	2007-10-04	Novel hcv inhibitor combinations and methods
TW200640482A (en)	2006-12-01	Variant forms of urate oxidase and use thereof
WO2005102392A3 (en)	2006-07-20	Combinations for treating hiv infection
ATE424894T1 (de)	2009-03-15	Zusammensetzung zur förderung des haarwachstums
WO2005121138A3 (en)	2009-03-05	Heterotricyclic compounds for use as hcv inhibitors
ATE538790T1 (de)	2012-01-15	Scopolamin für die behandlung von depression und ängstlichkeit
DE60015568D1 (de)	2004-12-09	Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
WO2006034001A3 (en)	2006-11-23	Methods of treating hiv infection
DK1147088T3 (da)	2006-05-15	6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
WO2005009366A3 (en)	2005-07-28	Restoring vascular function
ATE493176T1 (de)	2011-01-15	Verwendung von 3-positions-cyclosporin-derivaten für haarwachstum
EA200601392A1 (ru)	2006-12-29	Способы и композиции для лечения липодистрофии